Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAN-TU Platform Trial of E2814 With/Without Lecanemab in Dominantly Inherited Alzheimer's Disease
jRCT2031230113Phase 3Active, not recruiting
- Sponsor
- DIAN-TU
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of etalanetug and lecanemab in Alzheimer's disease (AD) (4 cohorts), sponsored by DIAN-TU. Primary endpoint: Primary: Change in tau PET (Cohort 1 symptomatic). Started Feb 2024; status: active, not recruiting.
02
Drugs
etalanetuglecanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031230113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230113.